I think one of the issues is the conditions being targeted are all such low incidence. Journalists, clinicians and the the public are essentially self-interested in the whole. The clinician self interest is about break-through treatments in their own field. Often public interest in treatments is related to their direct connection, ie affected by a condition, or have a link to someone affected (I've done some research in this area). I envisage, after a couple of phase 2 positive results, further adding to proof of concept for 2591, that more generalised ( on likely medical efficacy) statements will start to be issued. Once headlines start including autism, cognitive decline, brain trauma, etc there will be interest in all 3 categories of a scale we cant imagine at this stage.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-6202
-
-
- There are more pages in this discussion • 4,665 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.39 |
Change
-0.130(0.63%) |
Mkt cap ! $2.606B |
Open | High | Low | Value | Volume |
$20.60 | $20.77 | $20.37 | $2.492M | 121.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 242 | $20.38 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.40 | 722 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 68 | 20.430 |
6 | 203 | 20.420 |
2 | 157 | 20.410 |
3 | 232 | 20.400 |
8 | 654 | 20.390 |
Price($) | Vol. | No. |
---|---|---|
20.440 | 109 | 6 |
20.450 | 2040 | 9 |
20.460 | 308 | 5 |
20.470 | 368 | 7 |
20.480 | 621 | 7 |
Last trade - 14.37pm 15/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online